{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.5","upperLimit":"55.2","value":"54.33"},{"groupId":"OG001","lowerLimit":"53.0","upperLimit":"54.7","value":"53.88"},{"groupId":"OG002","lowerLimit":"53.4","upperLimit":"55.1","value":"54.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"313"},{"groupId":"OG001","value":"311"},{"groupId":"OG002","value":"321"}],"units":"Participants"}],"title":"CP: Day 1, Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.8","upperLimit":"55.5","value":"54.61"},{"groupId":"OG001","lowerLimit":"53.2","upperLimit":"54.9","value":"54.10"},{"groupId":"OG002","lowerLimit":"53.6","upperLimit":"55.4","value":"54.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"311"},{"groupId":"OG002","value":"317"}],"units":"Participants"}],"title":"CP: Day 1, Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.0","upperLimit":"55.7","value":"54.88"},{"groupId":"OG001","lowerLimit":"53.5","upperLimit":"55.1","value":"54.31"},{"groupId":"OG002","lowerLimit":"53.9","upperLimit":"55.6","value":"54.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"296"},{"groupId":"OG001","value":"309"},{"groupId":"OG002","value":"308"}],"units":"Participants"}],"title":"CP: Day 1, Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.3","upperLimit":"56.0","value":"55.16"},{"groupId":"OG001","lowerLimit":"53.7","upperLimit":"55.4","value":"54.53"},{"groupId":"OG002","lowerLimit":"54.1","upperLimit":"55.8","value":"54.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"300"},{"groupId":"OG002","value":"303"}],"units":"Participants"}],"title":"CP: Day 1, Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.6","upperLimit":"56.3","value":"55.43"},{"groupId":"OG001","lowerLimit":"53.9","upperLimit":"55.6","value":"54.74"},{"groupId":"OG002","lowerLimit":"54.4","upperLimit":"56.1","value":"55.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"295"},{"groupId":"OG002","value":"297"}],"units":"Participants"}],"title":"CP: Day 1, Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.9","upperLimit":"56.5","value":"55.70"},{"groupId":"OG001","lowerLimit":"54.1","upperLimit":"55.8","value":"54.96"},{"groupId":"OG002","lowerLimit":"54.6","upperLimit":"56.3","value":"55.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"277"},{"groupId":"OG002","value":"266"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.4","upperLimit":"57.1","value":"56.25"},{"groupId":"OG001","lowerLimit":"54.6","upperLimit":"56.2","value":"55.39"},{"groupId":"OG002","lowerLimit":"55.1","upperLimit":"56.8","value":"55.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"264"},{"groupId":"OG002","value":"243"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.9","upperLimit":"57.7","value":"56.80"},{"groupId":"OG001","lowerLimit":"55.0","upperLimit":"56.7","value":"55.82"},{"groupId":"OG002","lowerLimit":"55.6","upperLimit":"57.3","value":"56.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"242"},{"groupId":"OG002","value":"233"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.5","upperLimit":"58.2","value":"57.35"},{"groupId":"OG001","lowerLimit":"55.4","upperLimit":"57.1","value":"56.25"},{"groupId":"OG002","lowerLimit":"56.0","upperLimit":"57.8","value":"56.91"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"212"},{"groupId":"OG001","value":"227"},{"groupId":"OG002","value":"208"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.0","upperLimit":"58.8","value":"57.90"},{"groupId":"OG001","lowerLimit":"55.8","upperLimit":"57.6","value":"56.69"},{"groupId":"OG002","lowerLimit":"56.4","upperLimit":"58.3","value":"57.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"198"},{"groupId":"OG002","value":"189"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.5","upperLimit":"59.4","value":"58.45"},{"groupId":"OG001","lowerLimit":"56.1","upperLimit":"58.1","value":"57.12"},{"groupId":"OG002","lowerLimit":"56.9","upperLimit":"58.9","value":"57.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"148"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.9","upperLimit":"60.1","value":"59.00"},{"groupId":"OG001","lowerLimit":"56.5","upperLimit":"58.6","value":"57.55"},{"groupId":"OG002","lowerLimit":"57.3","upperLimit":"59.4","value":"58.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"131"},{"groupId":"OG002","value":"120"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.4","upperLimit":"60.7","value":"59.55"},{"groupId":"OG001","lowerLimit":"56.9","upperLimit":"59.1","value":"57.98"},{"groupId":"OG002","lowerLimit":"57.7","upperLimit":"60.0","value":"58.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"98"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.9","upperLimit":"61.3","value":"60.09"},{"groupId":"OG001","lowerLimit":"57.2","upperLimit":"59.6","value":"58.41"},{"groupId":"OG002","lowerLimit":"58.1","upperLimit":"60.5","value":"59.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"82"},{"groupId":"OG002","value":"77"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.4","upperLimit":"61.9","value":"60.64"},{"groupId":"OG001","lowerLimit":"57.6","upperLimit":"60.1","value":"58.84"},{"groupId":"OG002","lowerLimit":"58.5","upperLimit":"61.1","value":"59.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"64"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.8","upperLimit":"62.6","value":"61.19"},{"groupId":"OG001","lowerLimit":"57.9","upperLimit":"60.6","value":"59.28"},{"groupId":"OG002","lowerLimit":"58.9","upperLimit":"61.7","value":"60.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"52"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 11"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.3","upperLimit":"63.2","value":"61.74"},{"groupId":"OG001","lowerLimit":"58.3","upperLimit":"61.1","value":"59.71"},{"groupId":"OG002","lowerLimit":"59.3","upperLimit":"62.2","value":"60.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"37"}],"units":"Participants"}],"title":"MP/OP: Day 1, Cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.2","upperLimit":"57.9","value":"57.04"},{"groupId":"OG001","lowerLimit":"55.1","upperLimit":"56.9","value":"56.01"},{"groupId":"OG002","lowerLimit":"55.8","upperLimit":"57.5","value":"56.64"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"301"},{"groupId":"OG002","value":"297"}],"units":"Participants"}],"title":"End of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"332"},{"groupId":"OG001","value":"331"},{"groupId":"OG002","value":"335"}],"units":"Participants"}],"description":"National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (FOSI-18) is an 18-itemed participant completed questionnaire, designed to assess impact of cancer therapy on ovarian cancer-related symptoms. Based on numerical point scoring of symptoms. Includes three subscales: disease-related symptoms (10 items), treatment-related side effects (5) and general function/well-being (3). Participants rated their level of symptoms for each items using 5-point scale from 0=not at all to 4=very much. Items that were negatively framed, scores were reversed for analysis so that higher scores= good quality of life. Total symptom index: total of 18 scores, ranging from 0=severely symptomatic to 72=asymptomatic. Higher FOSI-18 scores= better functioning or lower symptom burden. MP applicable only for arms 'Chemotherapy followed by Avelumab' and 'Chemotherapy + Avelumab followed by Avelumab' and OP for 'Chemotherapy followed by Observation'.","dispersionType":"95% Confidence Interval","groups":[{"description":"In chemotherapy phase (CP),based on investigator's decision,participants received either:paclitaxel 175 milligrams per square meter (mg/m2) intravenous (IV) infusion,followed by carboplatin dose at area under curve (AUC) 5 or 6,IV infusion (carboplatin dose (mg) = Target AUC (mg\\*min/mL) x (glomerular filtration rate\\[GFR\\] mL/min + 25),and maximum carboplatin dose = target AUC x (150 mL/min) on Day 1 of Cycles 1 to 6; or Paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15, along with carboplatin dose at AUC 5 or 6, IV infusion over 1 hour on Day 1 of Cycle 1 to 6 (1 cycle=21 days). After completion of CP, participants without evidence of disease progression, received avelumab 10 mg/kg, over 1 hour IV infusion,once every 2 weeks on Days 1, 15, and 29 (1 cycle=42 days) in maintenance phase (MP) until confirmed progressive disease,unacceptable toxicity, or withdrawal of consent, or a maximum duration of 24 months. Participants were then followed up to a maximum of 36 months.","id":"OG000","title":"Chemotherapy Followed by Avelumab"},{"description":"In CP, based on investigator's decision, participants received either:paclitaxel 175 mg/m2,IV,followed by carboplatin dose at AUC 5 or 6,IV (carboplatin dose \\[milligrams\\](mg) = Target AUC (mg\\*min/mL) x GFR mL/min + 25),and maximum carboplatin dose = target AUC x (150 mL/min) on Day 1 of Cycles 1 to 6;or Paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15, along with carboplatin dose at AUC 5 or 6, IV infusion over 1 hour on Day 1 of Cycle 1 to 6 along with Avelumab 10 mg/kg administered as a 1-hour IV infusion once every 3 weeks for Cycle 1 to 6 ( 1 cycle=21 days).After completion of CP, participants without evidence of disease progression, received Avelumab IV, 10 mg/kg, once every 2 weeks on Days 1, 15, and 29 ( 1 cycle=42 days) in MP until confirmed progressive disease (PD), unacceptable toxicity, or withdrawal of consent, or a maximum duration of 24 months. Participants were then followed up to a maximum of 36 months.","id":"OG001","title":"Chemotherapy + Avelumab Followed by Avelumab"},{"description":"In CP, based on investigator's decision, participants received either: paclitaxel 175 mg/m2, IV infusion, followed by carboplatin dose at AUC 5 or 6, IV infusion (carboplatin dose \\[milligrams\\](mg) = Target AUC \\[milligrams\\*minute per milliliter\\] (mg\\*min/mL) x GFR mL/min + 25), and maximum carboplatin dose = target AUC x (150 mL/min) on Day 1 of Cycles 1 to 6; or Paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15, along with carboplatin dose at AUC 5 or 6, IV infusion over 1 hour on Day 1 of Cycle 1 to 6. Each cycle was of 21 days (3 weeks). After completion of CP, participants were followed for survival status until death or until study completion, whichever was earlier or a maximum duration of 24 months in observation phase. Participants were then followed up to a maximum of 36 months.","id":"OG002","title":"Chemotherapy Followed by Observation"}],"paramType":"MEAN","populationDescription":"The full analysis set included all randomized participants. Here, 'Number analyzed' = participants evaluable for this outcome measure at specified rows. Category titles 'MP/OP' imply which ever phase was applicable for the respective reporting arms.","reportingStatus":"POSTED","timeFrame":"CP: Pre-dose on Day 1 of Cycles 2 to 6 (1 cycle= 21 days); MP/OP: Day 1 of Cycles 1 to 12 (1 cycle= 42 days), End of treatment (any time up to Month 27)","title":"Functional Assessment of Ovarian Symptom Index- 18 (FOSI-18) Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}